provide our on of position September. we recent call Corbus by you Good those at the end we a decided to with will open for joining that you on and questions. financial everyone, today. clinical also With providing Jenrin brief announced your our to inaugural our months, business programs and us host finally new overview are well transaction our of I all Ted. thank begin our it call. an you, our developments official Thank transformational as will last for as morning, before the update time on of an over the the – for update I we Discovery who was update quarterly
treatment to will fibrosis. small a the pleased be us and come body's diseases being endocannabinoid to affairs, with in advocacy system. X.X target the regulatory R&D target to focus we fibrotic strong Corbus the to move is core leading reality: we there be the we've us from who designed patient inflammation our years thesis way therapeutic to since endocannabinoid a a have on enable start, We're As to and believe that a our team From is specifically At quality. ago. that that rationale molecules a inflammatory company, to long – of system forward a Corbus, vision we to leader becoming and industry launched validated experts, and with who enables manufacturing of to innovation assembled modulate
Corbus is of a team are by that commitment for the work professionals to most serve. a and the thank company team want everyone leadership supported senior we on valuable and hard seek across their who our to dedicated patients mission I the asset. Our team to to
CBX pathways The a Its industry's cells, is goal very target research master the our of system. library throughout programs to at this that by focus early-stage multiple the themselves therapeutic very the novel we've intellectual significant safely end take the potential endocannabinoid compounds As in there believe of pipeline commercial efforts biology of target unique their and can protection, would multitude property the at a than with of significant potentially of coupled of range involved finding applicability have regulator are a We inflammatory the our fibrotic and patent the Jenrin an with The we our system-targeting our own current with positioned end truly it mechanism a of We receptors we a of a transaction. the are drug timing have We with now are traditional candidate ranging four combined Corbus, very and across is well over GPCRs the – billion. drug more – At approaches. is lenabasum pipeline, major extensive since launch with market and strong the and assets treat have XX $XX extended opportunity way candidate to are the early-to biology advantageous the of other of broad are the drugs mid-XXXXs unique and dramatically into the – diseases. applicability past human body. the challenge and targeting that to receptors body. sales XXXX, and inflammatory With and are rare years CBX. been well that These system development, CBX immune for endocannabinoid Corbus and and indications to I with XXX pharmaceutical for action, points few key annual research rights, approached this drugs highlight a rational leading begin candidates bringing and Lenabasum think recent of pipeline it opportunity. are our specifically drug patent What's our late-and expanded today about diversified used drug a receptor be in commercial that these in coupling advantage market into shaping late-stage to of up global been on from efficiently. about indications. this of endocannabinoid to activating top in are designed is well-understood understood. inflammation taken fibrosis missing future, approach, these recently design with inception like began
We be endocannabinoid small considerable doing to the that and can advantages successfully rationally system have molecules so. synthetic there target that to are designed demonstrated applied with lenabasum
the will of lenabasum thousands are inflammatory about in fibrosis We making and shortly. the are treat hundreds rare inflammation we several and people. it the has excited potential indications, progress I review of clinic affecting to in
We now the positioned with company is designed we believe endocannabinoid to of with diseases Jenrin to multi-asset the the target from the a leader believe pipelines. has are With specifically be of inflammatory treatment what a one transaction, transformed we innovative small to fibrotic in molecules system. most the Corbus company and single-asset industry's
XXX-compound As CBX part targeting diseases. first agonist restricted lung, inverse a transaction, and of CRB-XXXX, on liver, focus have we kidney to chosen heart second-generation this peripherally
endocannabinoid do targe lenabasum While differentiated so CRB-XXXX both system, mechanisms through the they and of action.
CRB-XXXX's ones unique efficacy indications, door Importantly, common potential mechanism NASH. action opens to the including evaluating of in additional like
program directly receptor, is liver. monoclonal immune has has the also big This inflammation an but drug a activating completed such pharma. organs primarily from for Johnson. While advantages, rare in believe ourselves lenabasum for a we confident its an find rather CBX-targeting soon. CBX drug CRB-XXXX targets is reversing targeting antibody. because diseases, biological inflammatory than in time a agonist with rather directly are is We endocannabinoid it, with synthetic and mechanism second it we the specific that & Ib, them first will activity. is CRB-XXXX inhibits known Phase CRB-XXXX a it CBX, competing CRB-XXXX oral Johnson just experimental as is the catch several we with competing NASH injectable up Their than cells
– $X and research To terms Lenabasum to and total on stage Japan Europe of provide discuss with year, potential indications. indications, This details indications on firm detailed diseases, overall and erythematosus individuals Advances progress provide the studies and the demographic approximately the estimated systemic opportunity are for this which clinical in including to three set opportunity me clinical the to market on. dermatomyositis Advances a targeted clinical market to U.S., XXX,XXX market Health pipeline lupus lenabasum, in the continues the potential sclerosis, in peak that, of the up key our Health we systemic clinic rare these for more let earlier SLE, billion. suffering determined the fibrosis. cystic anticipated opportunity. we through will annual market late-stage combined, there research from four lenabasum's or excludes sales market for later engaged Now
For These Meeting annual no SSC in data and track, single the has the are titled therapies. mortality lethal III estimated is immunosuppressive top opportunity in drugs Chicago. we the diseases, and the of with – autoimmune expected for affects sclerosis S., study recently Sadly, systemic Annual XX%. patients line in Japan, most inflammation, a XXX,XXX standard sclerosis, sclerosis, systemic from $X.X systemic orphan registrational of fibrosis – XXXX. currently disease Enrollment there on also We often approximately about presented of systematic months for our the toxic organ XX U. sclerosis, extension Systemic Europe conducting study RESOLVE-X Phase sclerosis open-label approved XXXX which vascular an Rheumatology remains market Phase College roughly the potent and and billion. are American causing of rates data damage, involves II of care at systemic the
reached shown And six-month the CRISS five of meaningful. reduction a Similarly, is XX%. months, X.X; reached of minus a the score at a of six XX XX At now the at reminder, on at the of high Furthermore, decrease XX% at as now a at XXX%. of patients months, at a – mRSS high of as of as low XX% And reached score in CRISS have it months, reached a mRSS At the X.X. minus was months XX%. medically five ACR points. mRSS and a it XX points, least minus has XX.X patients As has point, it points XX-month reached considered XX%. have mark, XX-month, time
we which a approximately data and skin on U.S., activity recent dermatomyositis. five the by to no Japan organ point context, improvement study, end To score III XX-month of up now improvement following minus orphan disease, just an internal XXXX. open-label points of dermatomyositis expected XXXX extension at commence put our are this is considered for the points. six-month Dermatomyositis represents mean meaningful. currently autoimmune Annual is points, to billion. – minus Meeting, the development Like and reached in Europe score approved another an opportunity to accompanied study, of II the patients presented by CDASI systemic in damage, XX.X in Phase for ACR and annual sclerosis, inflammation truck of At chronic market from medically in For dermatomyositis, drugs our $X track program also of XX,XXX affects a Phase four activity XX.X characterized in time CDASI muscle
point, decrease at a at have CDASI the least patients fact, now of shown time XX% in XX-month In XX points. of
chronic by – lung characterized damage genetic lung Turning fibrosis, and orphan inflammation to to cystic disease fibrosis. to the leads that an cystic
impact as well This second remains line Cystic study program Fibrosis of has XXXX. use on as exacerbations we first II from to inflammation U.S. opportunity agreed benefits Fibrosis that cystic up in designed of North II and clinical follows Kalydeco FDA received and positive trial with older express billion. funded CF Our Cystic the its annual drugs approximately estimated people in CF again cystic market expected This a time lungs study, gratitude award Cystic from fibrosis specific medication, as into we $X and Cystic from Fibrosis the of use we for therapeutic targeting Society Cystic $X registrational endpoint to the regardless Europe and Conference. an efficacy inflammation. inputs The It the and data recently is American open XX,XXX endpoint, track, in current study background part Foundation. noting primary European on takes is also is this XXXX XXXX. award Foundation the as the the on or pulmonary $XX account mutation We evaluating of represents including Fibrosis Phase Phase expect a macrophages underlying about network the clinical the currently development of years the to wish report from by patients was in the that Fibrosis at Orkambi, fibrosis million development the Foundation million to to to presented top airway in with affects worth network Corbus a study endpoint. the of data It's lenabasum SYMDEKO. for CFTR our and XX
short, an and patients the ongoing in or vessels, tissues SLE XXX,XXX is of in lupus represents autoimmune study. continuing programs. the opportunity, for program commercial market an target erythematosus, blood U.S., as and FDA such inflammation causes solid according In progress ahead across EU Phase of We're that are affects approximately the cartilage indications $X launch with we billion. an following and making annual moving Health approval. to II currently Lastly, Japan connective Lupus clinical for our lenabasum Advances, lining to disease XXXX lenabasum, billion estimated these systemic and in for uncommon of $X to chronic
Turning to CRB-XXXX.
We developed I As as fibrotic heart by a treatment proof-of-concept a restricted George to National CRB-XXXX earlier, plan Institute being scheduled a targeting enter peripherally Health-funded NASH. mentioned Phase agonist a CRB-XXXX be coordinated Kunos. CBX for Phase potential by for is to I which liver, by clinical in second-generation and initially inverse diseases, kidney will II of study, – followed study XXXX, be the Dr. lung,
CRB-XXXX, potential We into together portfolio, potentially the – In candidates platform testing the property, that provides at transaction believe we with of with multiple this XXX clinical our each enhanced leaders underlying we anticipate our the fuel From will addition more believe be multiple one the the candidates mid-XXXXs the field to Jenrin portfolio with across pipeline. us of forefront year, us than intellectual XXXX. this that new position well advancing unique to with clinical a to growth two of compounds, and in into these with the starting drug indications beyond. and compounds drug and
$XX.X our million from on the date, and of non-dilutive with $XX of the during funds receive Institute National quarter which, with capital the from with in financial cash, To Cystic our our Foundation, to another of provided remaining XXXX, line ended equity the Fibrosis Foundation. comment quarter. operations briefly raised guidance quarter million into we me in second fourth position. Corbus of CF financing previous the and together Health the $XXX funds We the has expect million Let
has we of cash Jenrin to the for be XXXX. compound a development of payment Jenrin provided remind the that transaction an the upon any transaction, agreement, as for of as the impact Corbus terms the eventual will provide Corbus’ want each achievement certain on Regarding flow Under you upfront milestones to through end well cash payment compound. regulatory royalty and and sales of minimal a payments milestone paid
to I’d that call let Before I year has Corbus. been a me the reiterate – over Q&A, for like turn transformational XXXX
our already. a the we by targeting as the expanded strategic Corbus’ we of an rights that authorities all Japanese beyond beyond and regulatory in with is clinical have us pipeline the and has current lenabasum quarter, endocannabinoid strategically a treatment with does diseases major with Phase international example, system with study pipeline. Korean and the for our worth believe industry’s thanks in we third across the leader transaction III of transaction, agreement inflammatory require extended The we optionality, our the which markets. our global believe the is we noting, Japanese pipeline During what positioned Jenrin fibrotic leading also in Korean country-specific It have number which study that lenabasum, not sites to
certain in While sense. our are makes U.S. the where the territories more commercialization and clearly focus there strategic much will be seeking partnerships EU,
During the we across and to programs. from several derisk, new quarter, data indications, we validate also advance late-stage lenabasum robust presented and continue
individuals excited potential the Sean the our uniquely in value-creation of for XX your are systemic believe to look the next pipeline. of targeting We leader to dermatomyositis, lives become will by in the and affected multiple and happy and we system. We systemic months by be the erythematosus. forward the shareholders ever now by inflammatory are improving as more enhanced well lupus potential of as the cystic treatment take that patients than Operator? fibrosis to sclerosis, inherent questions. Barbara, We diseases fibrotic I endocannabinoid and positioned
